Patents Examined by David M Shim
  • Patent number: 11737995
    Abstract: Methods for treating or preventing kidney diseases and fibrosis, such as chronic kidney disease (CKD), kidney fibrosis, heart fibrosis, uterine fibrosis, and cystic fibrosis, with compounds of Formulae (I), (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof.
    Type: Grant
    Filed: January 24, 2022
    Date of Patent: August 29, 2023
    Assignee: Espervita Therapeutics, Inc.
    Inventors: Daniela Carmen Oniciu, Gregory R. Steinberg, Spencer Heaton, Roger Schofield Newton, James Stuart Vincent Lally, Jaya Gautam
  • Patent number: 11731968
    Abstract: Tricyclic mitogen-activated protein kinases kinase 4 (MKK4) inhibitor compounds useful for promoting liver regeneration or reducing hepatocyte death by selectively inhibiting MKK4 over protein kinases JNK and MKK7.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: August 22, 2023
    Assignee: HepaRegeniX GmbH
    Inventors: Michael Juchum, Roland Selig, Stefan Laufer, Wolfgang Albrecht
  • Patent number: 11633400
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to 4-(2-hydroxyethyl)-morpholine is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: April 25, 2023
    Assignee: MERCK PATENT GMBH
    Inventors: Rudolf Moser, Viola Groehn, Ruth Boehni Stamm, Fritz Blatter, Martin Szelagiewicz